Outcomes and Adverse Effects of Baricitinib Versus Tocilizumab in the Management of Severe COVID-19.

ABSTRACT:

Objectives

The National Institutes of Health and Infectious Diseases Society of America guidelines recommend tocilizumab or baricitinib in the management of severe COVID-19. Despite clinical trials on the individual agents, there are no large-scale studies comparing the two agents to guide the selection of one versus the other. The purpose of this study was to compare the outcomes and adverse effects of baricitinib versus tocilizumab in the management of severe COVID-19.

Design

Retrospective, observational cohort study.

Setting

Eleven acute care hospitals in a large health system in Georgia.

Patients

Adult patients with severe COVID-19 who received at least one dose of either baricitinib or tocilizumab between June 2021 and October 2021.

Interventions

No

SUBMITTER: Peterson JH 

PROVIDER: S-EPMC9936841 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature